Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Europe has given limited approval to Lilly's Alzheimer's drug, President Trump has announced a trade deal with the EU, Delta ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, as a part of the company's growing development programmefor the ...

EMA committee recommends approval of Eli Lilly’s donanemab in early symptomatic Alzheimer's disease: Indianapolis Monday, July 28, 2025, 13:00 Hrs [IST] Eli Lilly and Company an ...

Eli Lilly & Company (NYSE: LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...

While the drugs cannot cure or reverse the symptoms, they can slow the progression of the disease. Read more at ...